JP2002516900A5 - - Google Patents

Download PDF

Info

Publication number
JP2002516900A5
JP2002516900A5 JP2000552085A JP2000552085A JP2002516900A5 JP 2002516900 A5 JP2002516900 A5 JP 2002516900A5 JP 2000552085 A JP2000552085 A JP 2000552085A JP 2000552085 A JP2000552085 A JP 2000552085A JP 2002516900 A5 JP2002516900 A5 JP 2002516900A5
Authority
JP
Japan
Prior art keywords
compound
solvate
pharmaceutically acceptable
preparing
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000552085A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002516900A (ja
JP3554539B2 (ja
Filing date
Publication date
Priority claimed from SE9801992A external-priority patent/SE9801992D0/xx
Application filed filed Critical
Publication of JP2002516900A publication Critical patent/JP2002516900A/ja
Application granted granted Critical
Publication of JP3554539B2 publication Critical patent/JP3554539B2/ja
Publication of JP2002516900A5 publication Critical patent/JP2002516900A5/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000552085A 1998-06-04 1999-05-31 新規な3−アリール−2−ヒドロキシプロピオン酸誘導体i Expired - Fee Related JP3554539B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9801992A SE9801992D0 (sv) 1998-06-04 1998-06-04 New 3-aryl-2-hydroxypropionic acid derivative I
SE9801992-0 1998-06-04
PCT/SE1999/000941 WO1999062872A1 (en) 1998-06-04 1999-05-31 New 3-aryl-2-hydroxypropionic acid derivative (i)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2003273428A Division JP2004043480A (ja) 1998-06-04 2003-07-11 新規な3−アリール−2−ヒドロキシプロピオン酸誘導体iの中間体

Publications (3)

Publication Number Publication Date
JP2002516900A JP2002516900A (ja) 2002-06-11
JP3554539B2 JP3554539B2 (ja) 2004-08-18
JP2002516900A5 true JP2002516900A5 (cg-RX-API-DMAC7.html) 2005-04-28

Family

ID=20411587

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000552085A Expired - Fee Related JP3554539B2 (ja) 1998-06-04 1999-05-31 新規な3−アリール−2−ヒドロキシプロピオン酸誘導体i
JP2003273428A Withdrawn JP2004043480A (ja) 1998-06-04 2003-07-11 新規な3−アリール−2−ヒドロキシプロピオン酸誘導体iの中間体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2003273428A Withdrawn JP2004043480A (ja) 1998-06-04 2003-07-11 新規な3−アリール−2−ヒドロキシプロピオン酸誘導体iの中間体

Country Status (39)

Country Link
US (5) US6258850B1 (cg-RX-API-DMAC7.html)
EP (1) EP1084103B1 (cg-RX-API-DMAC7.html)
JP (2) JP3554539B2 (cg-RX-API-DMAC7.html)
KR (1) KR100625152B1 (cg-RX-API-DMAC7.html)
CN (2) CN1311772A (cg-RX-API-DMAC7.html)
AR (2) AR020875A1 (cg-RX-API-DMAC7.html)
AT (1) ATE246674T1 (cg-RX-API-DMAC7.html)
AU (1) AU752261B2 (cg-RX-API-DMAC7.html)
BR (1) BR9910928A (cg-RX-API-DMAC7.html)
CA (1) CA2333938C (cg-RX-API-DMAC7.html)
CZ (1) CZ297424B6 (cg-RX-API-DMAC7.html)
DE (1) DE69910203T2 (cg-RX-API-DMAC7.html)
DK (1) DK1084103T3 (cg-RX-API-DMAC7.html)
DZ (1) DZ2800A1 (cg-RX-API-DMAC7.html)
EE (1) EE04772B1 (cg-RX-API-DMAC7.html)
EG (1) EG24140A (cg-RX-API-DMAC7.html)
ES (1) ES2205844T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20000782B1 (cg-RX-API-DMAC7.html)
HU (1) HUP0103376A3 (cg-RX-API-DMAC7.html)
ID (1) ID28833A (cg-RX-API-DMAC7.html)
IL (1) IL139636A (cg-RX-API-DMAC7.html)
IS (1) IS2071B (cg-RX-API-DMAC7.html)
MA (1) MA26635A1 (cg-RX-API-DMAC7.html)
MY (1) MY117785A (cg-RX-API-DMAC7.html)
NO (1) NO323426B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ508452A (cg-RX-API-DMAC7.html)
PL (1) PL195189B1 (cg-RX-API-DMAC7.html)
PT (1) PT1084103E (cg-RX-API-DMAC7.html)
RS (1) RS49688B (cg-RX-API-DMAC7.html)
RU (1) RU2214999C2 (cg-RX-API-DMAC7.html)
SA (1) SA99200304B1 (cg-RX-API-DMAC7.html)
SE (1) SE9801992D0 (cg-RX-API-DMAC7.html)
SK (1) SK284642B6 (cg-RX-API-DMAC7.html)
TN (1) TNSN99108A1 (cg-RX-API-DMAC7.html)
TR (1) TR200003581T2 (cg-RX-API-DMAC7.html)
TW (1) TW446696B (cg-RX-API-DMAC7.html)
UA (1) UA71912C2 (cg-RX-API-DMAC7.html)
WO (1) WO1999062872A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200006774B (cg-RX-API-DMAC7.html)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8702758D0 (en) * 1987-02-06 1987-03-11 Wellcome Found Treatment of disease
JP4798814B2 (ja) 1997-01-07 2011-10-19 アミリン・ファーマシューティカルズ,インコーポレイテッド 食物摂取低減用のエキセンジンおよびそのアゴニストの使用
EP1124807A1 (en) * 1997-10-27 2001-08-22 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
TW574193B (en) 1999-12-03 2004-02-01 Astrazeneca Ab Novel phenalkyloxy-phenyl derivatives, pharmaceutical composition containing the same and their uses
US7084177B2 (en) 1999-12-03 2006-08-01 Astrazeneca Ab Comminuted form of(S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl] propanoic acid
SE9904415D0 (sv) * 1999-12-03 1999-12-03 Astra Ab New process
AU773777B2 (en) * 1999-12-03 2004-06-03 Astrazeneca Ab Crystalline form of (S)-2 ethoxy-3-(4-(2-(4-methanesulfonyloxyphenyl) ethoxy) phenyl) propanoic acid
SE9904421D0 (sv) * 1999-12-03 1999-12-03 Astra Ab New compounds
WO2001051078A1 (en) * 2000-01-10 2001-07-19 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
US6559335B2 (en) 2000-09-22 2003-05-06 Dr. Reddy's Laboratories Limited Process for the preparation of 3-aryl-2-hydroxy propanoic acid
EP1695716A2 (en) 2000-12-26 2006-08-30 Sankyo Company, Limited Medicinal compositions containing diuretics and insulin sensitizers
SE0101386D0 (sv) 2001-04-20 2001-04-20 Astrazeneca Ab New compounds
US20050014955A1 (en) * 2001-06-01 2005-01-20 Robert Ehrl Process for the preapartion 3-aryl-2-hydroxypropionic acid derivative
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
SE0101978D0 (sv) 2001-06-01 2001-06-01 Astrazeneca Ab New compounds
SE0101981D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
SE0101980D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
CN1543451A (zh) 2001-06-07 2004-11-03 过氧化物酶体增生剂激活的受体的调节剂
RU2341513C2 (ru) * 2001-06-12 2008-12-20 Веллстат Терапьютикс Корпорейшн Соединения для лечения метаболических заболеваний
UA82835C2 (en) 2001-12-03 2008-05-26 Reddys Lab Ltd Dr ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0314079D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0229931D0 (en) * 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
AU2002351752A1 (en) 2001-12-29 2003-07-30 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
SE0201005D0 (sv) * 2002-04-02 2002-04-02 Astrazeneca Ab New Process
US20050119314A1 (en) * 2002-04-05 2005-06-02 Sankyo Company, Limited Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent
CA2489834C (en) * 2002-06-20 2006-10-03 Astrazeneca Ab Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
SE0201936D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
SE0201937D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
US7351858B2 (en) * 2002-06-20 2008-04-01 Astrazeneca Ab Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
DE10308351A1 (de) 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308353A1 (de) 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308352A1 (de) 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
EP1636164A2 (en) * 2003-06-06 2006-03-22 Cadila Healthcare Ltd. Process for preparing 3-aryl-2-hydroxy propanoic acid derivatives without resolution
GB0314130D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314131D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314075D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314078D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314260D0 (en) 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
EP2428516A1 (en) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US20070142472A1 (en) * 2003-11-27 2007-06-21 Tohru Yokozawa Process for producing optically active 3-(4-hydroxyphenyl)proprionic acids
EP1586573B1 (en) 2004-04-01 2007-02-07 Sanofi-Aventis Deutschland GmbH Oxadiazolones, processes for their preparation and their use as pharmaceuticals
JP4177435B2 (ja) 2004-04-03 2008-11-05 アストラゼネカ アクチボラグ 治療薬
FR2872159B1 (fr) * 2004-06-28 2007-10-05 Merck Sante Soc Par Actions Si Nouveaux derives acides carboxyliques phenyliques et leur utilisation dans le traitement du diabete
TW200608967A (en) 2004-07-29 2006-03-16 Sankyo Co Pharmaceutical compositions containing with diabetic agent
CN102600144A (zh) * 2005-03-08 2012-07-25 奈科明有限责任公司 治疗糖尿病的罗氟司特
DE102005026762A1 (de) 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
AU2007274598A1 (en) * 2006-07-21 2008-01-24 Lupin Limited Antidiabetic azabicyclo [3. 1. 0] hexan compounds
KR100958831B1 (ko) * 2006-09-19 2010-05-24 주식회사유한양행 헤테로아릴피리미딘 유도체, 이들의 제조방법, 및 이들을포함하는 조성물
US20090082441A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched tesaglitazar
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
MX366925B (es) 2010-11-04 2019-07-31 Albireo Ab Inhibidores de ibat para el tratamiento de enfermedades hepaticas.
US20130236541A1 (en) 2010-11-08 2013-09-12 Albireo Ab Pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
EP2758041B1 (de) 2011-09-20 2021-01-13 Basf Se Niedermolekulare modulatoren des kälte-menthol-rezeptors trpm8 und deren verwendung
BR112015024859A2 (pt) * 2013-03-27 2017-10-10 Pfizer Ireland Pharmaceuticals processo e intermediários para a preparação de pregabalina
MX2016000724A (es) * 2013-07-22 2016-04-13 Metabolic Solutions Dev Co Llc Compuestos de reserva de los receptores activados del proliferador de peroxisoma (ppar) para el tratamiento de enfermedades metabolicas.
EP4615433A1 (en) 2022-11-08 2025-09-17 Genfit Ppar-alpha/gamma agonist for use in the treatment of liver failure

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4114417A (en) * 1977-06-27 1978-09-19 Schmelzer Corporation Method and apparatus for making metal parts
US4479005A (en) * 1982-12-16 1984-10-23 The Dow Chemical Company Selective preparation of isomers and enantiomers of cyclopropane carboxylic acids
FR2653119B1 (fr) 1989-10-18 1994-08-05 Lipha Nouveaux aryloxy alcoyl benzenes, leurs procedes de preparation et les compositions pharmaceutiques en renfermant.
US5068345A (en) * 1989-10-30 1991-11-26 Eastman Kodak Company Oxazolidinone aldol adduct
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
GB9114948D0 (en) * 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
SK695A3 (en) * 1992-07-03 1995-07-11 Smithkline Beecham Plc Heterocyclic compounds method of their production and using
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
US5648541A (en) * 1995-09-28 1997-07-15 Nps Pharmaceuticals, Inc. Chiral reductions of imines leading to the syntheses of optically active amines
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
RU2169141C2 (ru) * 1996-04-04 2001-06-20 Санкио Компани Лимитед Производные фенилалкилкарбоновой кислоты и фармацевтическая композиция на их основе
BR9812772A (pt) * 1997-10-27 2000-10-10 Reddy Research Foundation "compostos tricìclicos inéditos e o seu emprego na medicina;processo para a sua preparação e composições farmacêuticas contendo os mesmos"
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
MA26634A1 (fr) * 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801990D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl propionic acid derivatives and analogs

Similar Documents

Publication Publication Date Title
RU2214999C2 (ru) Производное 3-арил-2-гидроксипропионовой кислоты, способ его получения(варианты), фармацевтический препарат, способ лечения и промежуточный продукт
RU2000130189A (ru) Новое производное i 3-арил-2-гидроксипропионовой кислоты
JP2002508375A5 (cg-RX-API-DMAC7.html)
CS208664B2 (en) Method of making the new r,s-n-/2-phenyl-2-hydroxyethyl/-1-alkyl-3-/4-substituted phenyl/propylamines
TW200920374A (en) Rosuvastatin calcium in solid state, pharmaceutical composition comprising the same, and use thereof
JP2002513793A5 (cg-RX-API-DMAC7.html)
JP6215399B2 (ja) ナルトレキソンの製造方法
JP2009161544A (ja) チアゾリジンジオン誘導体および抗糖尿病薬としてのその使用
JP2005513014A5 (cg-RX-API-DMAC7.html)
US6939856B2 (en) Method for preparing dexchlor tannate
KR20040020926A (ko) 중수소화된 엔-치환 및 α-치환 디페닐알콕시 아세트산아미노 알킬 에스테르 및 이 화합물을 포함한 의약품
CA1172170A (en) Antiviral alpha, alpha-dialkyl adamantylethylamines
JPH0725724B2 (ja) トラネキサム酸亜鉛化合物
KR100601244B1 (ko) 티아졸리딘디온 유도체 및 그의 당뇨병약으로서의 용도
RU2004124840A (ru) Твердые соли бензазепиновых соединений и их применение при получении фармацевтических соединений
RU2007143025A (ru) Полиморфизм додекагидроклопента[а]фенантренилового эфира тиофенкарбоновой кислоты
JPS6248657A (ja) 抗炎症活性および鎮痛活性を有する化合物および組成物
JP2004532265A5 (cg-RX-API-DMAC7.html)
HUP0203790A2 (hu) (6-Metoxi-2-naftil)-ecetsav prodrugokat tartalmazó gyógyszerkészítmények alkalmazása gyulladás kezelésére
JP2002536442A5 (cg-RX-API-DMAC7.html)
JP2003520835A5 (cg-RX-API-DMAC7.html)
CN1080851A (zh) 生长激素释放抑制因子的增强剂
CN111574432A (zh) 一种可溶性环氧水解酶和γ-氨基丁酸双重抑制剂及用途
NZ199929A (en) 1-(1,3-benzodioxol-5-yl)-2-pyrrolidinone and pharmaceutical compositions
JP2005506335A5 (cg-RX-API-DMAC7.html)